Soleno Therapeutics Inc (NAS:SLNO)

$ 52.7 -0.94 (-1.75%) Market Cap: 2.05 Bil Enterprise Value: 1.82 Bil PE Ratio: 0 PB Ratio: 7.21 GF Score: 38/100

Soleno Therapeutics Inc Randomized Withdrawal Period of Study C602 Topline Results Call Transcript
Sep 26, 2023
Soleno Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 26, 2023
Soleno Therapeutics Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) Transcript
Apr 03, 2023
Soleno Therapeutics Inc at Destiny-PWS Transcript
Oct 20, 2020

Soleno Therapeutics Inc Randomized Withdrawal Period of Study C602 Topline Results Call Transcript

Sep 26, 2023 / 01:00PM GMT

Release Date Price: $26.8 (+504.97%)

Transcript

Operator

Greetings. Welcome to Soleno Therapeutics randomized withdrawal period of Study C602 topline results. (Operator Instructions) Please note this conference is being recorded.

At this time, I'll now turn the floor over to Brian Ritchie with LifeSci Advisors. Brian, you may now begin.

Brian Ritchie

LifeSci Advisors, LLC - IR

Thank you, operator. Thank you all for joining us this morning. With me on today's call are Soleno's Chief Executive Officer, Dr. Anish Bhatnagar; the company's Chief Financial Officer, Jim Mackaness; and Dr. Jennifer Miller, Professor of Pediatrics in the Division of Endocrinology at the University of Florida. This morning, Soleno issued a news release announcing top-line results from the company's randomized withdrawal period of Study C602, evaluating DCCR tablets for patients with Prader-Willi syndrome.

Please note that certain information discussed on the call today is covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that, during this call, Soleno management

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.